BMS Spins Off Mead Johnson In IPO, Retaining Majority Control
This article was originally published in The Tan Sheet
Executive Summary
Bristol-Myers Squibb will spin off its Mead Johnson infants and children nutritional products business in an initial public offering of shares rather than sell the unit, the firm says
You may also be interested in...
People In Brief
Mead Johnson replaces IR exec
Dutch Firm Vemedia Partners Outside The Box To Thrive During Recession
Unconventional partnerships may help small and mid-sized consumer health care firms survive or even thrive during the recession says Yvan Vindevogel, CEO of Vemedia Pharma, a European consumer health care firm
BMS Divests Indonesian OTC Business, Continues Biopharma Consolidation
Japanese firm Taisho Pharmaceutical will acquire nearly all shares of Bristol-Myers Squibb's Asian OTC subsidiary